These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 22716077

  • 1. Cardiovascular therapeutics targets on the NO-sGC-cGMP signaling pathway: a critical overview.
    Evora PR, Evora PM, Celotto AC, Rodrigues AJ, Joviliano EE.
    Curr Drug Targets; 2012 Aug; 13(9):1207-14. PubMed ID: 22716077
    [Abstract] [Full Text] [Related]

  • 2. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
    Boerrigter G, Burnett JC.
    Cardiovasc Drug Rev; 2007 Aug; 25(1):30-45. PubMed ID: 17445086
    [Abstract] [Full Text] [Related]

  • 3. The Endothelium-Dependent Nitric Oxide-cGMP Pathway.
    Mónica FZ, Bian K, Murad F.
    Adv Pharmacol; 2016 Aug; 77():1-27. PubMed ID: 27451093
    [Abstract] [Full Text] [Related]

  • 4. Structure and regulation of soluble guanylate cyclase.
    Derbyshire ER, Marletta MA.
    Annu Rev Biochem; 2012 Aug; 81():533-59. PubMed ID: 22404633
    [Abstract] [Full Text] [Related]

  • 5. Exploring the potential of NO-independent stimulators and activators of soluble guanylate cyclase for the medical treatment of erectile dysfunction.
    Gur S, Kadowitz PJ, Hellstrom WJ.
    Curr Pharm Des; 2010 May; 16(14):1619-33. PubMed ID: 20201788
    [Abstract] [Full Text] [Related]

  • 6. Erectile Dysfunction in Heme-Deficient Nitric Oxide-Unresponsive Soluble Guanylate Cyclase Knock-In Mice.
    Decaluwé K, Pauwels B, Boydens C, Thoonen R, Buys ES, Brouckaert P, Van de Voorde J.
    J Sex Med; 2017 Feb; 14(2):196-204. PubMed ID: 28161078
    [Abstract] [Full Text] [Related]

  • 7. Soluble Guanylate Cyclase Stimulators and Activators: Where are We and Where to Go?
    Xiao S, Li Q, Hu L, Yu Z, Yang J, Chang Q, Chen Z, Hu G.
    Mini Rev Med Chem; 2019 Feb; 19(18):1544-1557. PubMed ID: 31362687
    [Abstract] [Full Text] [Related]

  • 8. Soluble Guanylate Cyclase Stimulators and Activators.
    Sandner P, Zimmer DP, Milne GT, Follmann M, Hobbs A, Stasch JP.
    Handb Exp Pharmacol; 2021 Feb; 264():355-394. PubMed ID: 30689085
    [Abstract] [Full Text] [Related]

  • 9. Activators and stimulators of soluble guanylate cyclase counteract myofibroblast differentiation of prostatic and dermal stromal cells.
    Zenzmaier C, Kern J, Heitz M, Plas E, Zwerschke W, Mattesich M, Sandner P, Berger P.
    Exp Cell Res; 2015 Nov 01; 338(2):162-9. PubMed ID: 26410556
    [Abstract] [Full Text] [Related]

  • 10. Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence.
    Sandner P, Stasch JP.
    Respir Med; 2017 Jan 01; 122 Suppl 1():S1-S9. PubMed ID: 28341058
    [Abstract] [Full Text] [Related]

  • 11. Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure.
    Breitenstein S, Roessig L, Sandner P, Lewis KS.
    Handb Exp Pharmacol; 2017 Jan 01; 243():225-247. PubMed ID: 27900610
    [Abstract] [Full Text] [Related]

  • 12. Low plasma levels of L-arginine, impaired intraplatelet nitric oxide and platelet hyperaggregability: implications for cardiovascular disease in depressive patients.
    Pinto VL, de Souza PF, Brunini TM, Oliveira MB, Moss MB, Siqueira MA, Ferraz MR, Mendes-Ribeiro AC.
    J Affect Disord; 2012 Oct 01; 140(2):187-92. PubMed ID: 22424639
    [Abstract] [Full Text] [Related]

  • 13. Nitric oxide-independent down-regulation of soluble guanylyl cyclase by bacterial endotoxin in astroglial cells.
    Baltrons MA, García A.
    J Neurochem; 1999 Nov 01; 73(5):2149-57. PubMed ID: 10537075
    [Abstract] [Full Text] [Related]

  • 14. Differential involvement of signaling pathways in the regulation of growth hormone release by somatostatin and growth hormone-releasing hormone in orange-spotted grouper (Epinephelus coioides).
    Wang B, Qin C, Zhang C, Jia J, Sun C, Li W.
    Mol Cell Endocrinol; 2014 Feb 15; 382(2):851-9. PubMed ID: 24183819
    [Abstract] [Full Text] [Related]

  • 15. Cardiovascular effects of modulators of soluble guanylyl cyclase activity.
    Hoenicka M, Schmid C.
    Cardiovasc Hematol Agents Med Chem; 2008 Oct 15; 6(4):287-301. PubMed ID: 18855642
    [Abstract] [Full Text] [Related]

  • 16. Increased nitrovasodilator sensitivity in endothelial nitric oxide synthase knockout mice: role of soluble guanylyl cyclase.
    Brandes RP, Kim D, Schmitz-Winnenthal FH, Amidi M, Gödecke A, Mülsch A, Busse R.
    Hypertension; 2000 Jan 15; 35(1 Pt 2):231-6. PubMed ID: 10642303
    [Abstract] [Full Text] [Related]

  • 17. Guanylate cyclase and the .NO/cGMP signaling pathway.
    Denninger JW, Marletta MA.
    Biochim Biophys Acta; 1999 May 05; 1411(2-3):334-50. PubMed ID: 10320667
    [Abstract] [Full Text] [Related]

  • 18. Molecular variants of soluble guanylyl cyclase affecting cardiovascular risk.
    Wobst J, Rumpf PM, Dang TA, Segura-Puimedon M, Erdmann J, Schunkert H.
    Circ J; 2015 May 05; 79(3):463-9. PubMed ID: 25746521
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Phosphorylation of vasodilator-stimulated phosphoprotein: a consequence of nitric oxide- and cGMP-mediated signal transduction in brain capillary endothelial cells and astrocytes.
    Sporbert A, Mertsch K, Smolenski A, Haseloff RF, Schönfelder G, Paul M, Ruth P, Walter U, Blasig IE.
    Brain Res Mol Brain Res; 1999 Apr 20; 67(2):258-66. PubMed ID: 10216224
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.